Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
Friday, June 21, 2024Jazz Pharmaceuticals plc today announced topline results from the Phase b clinical trial evaluating the efficacy and safety of suvecaltamide an investigational highly selective and statedependent modulator of Ttype calcium channels
Basilea Partners Oncology Drug Candidate Lisavanbulin With Glioblastoma Foundation
Thursday, June 20, 2024Basilea Pharmaceutica Ltd Allschwil a biopharmaceutical company with marketed products dedicated to helping patients suffering from severe bacterial or fungal infections today announced
Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically
Thursday, June 20, 2024Theralase Technologies Inc a clinical stage pharmaceutical company dedicated to the research and development of light andor radiation activated small molecules and their formulations intended for the safe and effective
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
Wednesday, June 19, 2024Ligand Pharmaceuticals Incorporated today announced that its collaborator Merck known as MSD outside the United States and Canada has received approval
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
Wednesday, June 19, 2024Arch Biopartners Inc announced today that the University of Calgarys Conjoint
Pyros Pharmaceuticals Announces FDA Approval of VIGAFYDE™ (vigabatrin) as the First and Only Ready-to-Use Vigabatrin Oral Solution
Tuesday, June 18, 2024Pyros Pharmaceuticals Inc a leader in the development of enhanced specialty pharmaceuticals for rare diseases announced today that the US Food and Drug
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Tuesday, June 18, 2024Inhibikase Therapeutics Inc a clinicalstage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinsons disease
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
Monday, June 17, 2024Innate Pharma SA announced today that updated efficacy and safety results from the doseescalation part of the Phase study with SARIPH an investigational CD targeting Natural Killer Cell Engager from a joint research collaboration
FDA Approves BLINCYTO® (Blinatumomab) in CD19-positive Philadelphia Chromosome-negative B-cell Precursor Acute Lymphoblastic Leukemia (B-ALL) in the Consolidation Phase
Saturday, June 15, 2024Amgen today announced the US Food and Drug Administration has approved BLINCYTO for the treatment of adult and pediatric patients one month
Cantargia Reports Further Progress in Ongoing Phase 1 Clinical Trial With CAN10
Saturday, June 15, 2024Cantargia today reported progress in the ongoing phase clinical trial of the CAN antibody Seven dose groups have now been concluded without any safety concerns Furthermore additional receptor occupancy studies confirm that CAN
